Monte Rosa Therapeutics shares slipped premarket after the company priced a $300 million public offering at $24 per share, a 5.1% discount to its prior close. The deal includes common stock and pre-funded warrants, with an option for underwriters to buy additional shares. The offering is expected to close around January 12, 2026.